Cyanotech Corporation engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company sells its products as packaged consumer products through distributors, retailers, and online channels, and direct to consumers, as well as in bulk form to manufacturers, formulators, and distributors. Cyanotech Corporation was incorporated in 1983 and is headquartered in Kailua-Kona, Hawaii.
IPO Year:
Exchange: NASDAQ
Website: cyanotech.com
Cyanotech Corporation (Nasdaq Capital Market: CYAN), the world innovation leader in the cultivation and manufacture of microalgae for health and nutrition, including BioAstin® Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica®, today announces the appointment of Collette Kakuk as Chief Strategic and Commercial Officer. Ms. Kakuk brings an impressive background in business development, strategy, and marketing to add significant value to Cyanotech's growing stable of products. Her industry experience, combined with a passionate drive for sustainable and authentic product sourcing, makes her an ideal addition to Cyanotech's executive team. Recognizing growing global interest in microalgae
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
4 - CYANOTECH CORP (0000768408) (Issuer)
Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2025, ended June 30, 2024. Commenting on the first quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "This quarter's net sales increased 15% as compared to prior year primarily due to increased sales of Astaxanthin in both our bulk and packaged markets. As we continue to expand our product offerings, we were excited to launch our Hawaiian Spirulina® gummies in May to complement the Astaxanthin gummy product." "Our growth in sales f
Cyanotech Corporation (OTCQB Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2024, ended March 31, 2024. Commenting on the fiscal year results (changes shown vs. fiscal 2023), Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Although the year was filled with challenges, our team effectively managed spending, production and inventory to conclude the year with only slightly increased debt of $209,000. As we look forward to this next year, and the increasing interest we are currently seeing in our products along with new product offe
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the third quarter and first nine months of fiscal year 2024, ended December 31, 2023. Commenting on the third quarter fiscal year 2024 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "The macroeconomic environment led to lower sales across the portfolio on a year-to-date basis, being driven particularly by Spirulina bulk sales. Industry data shows consumers are not pulling back from dietary supplements, but they have begun trading down to private label brands to save on c
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter and first six months of fiscal year 2024, ended September 30, 2023. Commenting on the second quarter fiscal year 2024 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "The sales in the quarter are trending in the right direction with a 23.1% increase versus prior year. We generated cash flow from operations in the quarter of $0.8 million as we manage our spend in line with customer demand." "We continue to focus on driving demand in the naturally deriv
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2024, ended June 30, 2023. Commenting on the first quarter fiscal year 2024 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "This quarter we continue to see the impact of consumers shifting their spend from goods to experiences and services and reallocation of spending related to the high cost of living. Due to these shifting consumer trends, we have added a new position to the Company, Chief Strategic and Commercial Officer, to oversee an
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2023, ended March 31, 2023. Commenting on the fiscal year results (changes shown vs. fiscal 2022), Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Fiscal year 2023 was a challenging year as a result of a number of macroeconomic events and timing of sales. Consumers shifted their spend from goods to experiences and services. Lower sales in the bulk business were due in part to inventory adjustments after the global supply chain issues eased and l
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the third quarter and first nine months of fiscal year 2023, ended December 31, 2022. Commenting on the third quarter fiscal year 2023 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Sales in the third quarter improved by $712,000, or 14%, compared to the second quarter, as we saw modest improvement in consumer movement on both finished goods and bulk sales. However, both of our online finished good sales and our international bulk sales are still not performing to histori
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter and first six months of fiscal year 2023, ended September 30, 2022. Commenting on the second quarter fiscal 2023 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "The financial results for the quarter, compared to the same period last year, had net sales decrease driven by a confluence of events, including the increased U.S. dollar exchange rate affecting international sales, lower sales in the bulk business, primarily in Asia, due in part to inventory adj
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2023, ended June 30, 2022. Commenting on the first quarter fiscal 2023 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "The disappointing results in the first quarter were driven primarily by the $2.2 million decrease in sales and a higher cost per kilo of astaxanthin. Lower sales in the quarter related to timing of shipments to a Nutrex customer as we transitioned to their selling platform in the prior year, as well as a decrease in bulk spi
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2022, ended March 31, 2022. Commenting on the fiscal year results (changes shown vs. fiscal 2021), Cyanotech's Chief Executive Officer Emeritus and Chief Scientific Officer, Gerald R. Cysewski, Ph.D., said: "Net sales increased to $36.0 million in the fiscal year, 11.2% over the prior year, with an improved gross profit as a result of lower cost of spirulina due to higher production volumes and astaxanthin as a result of production efficiencies. We generated $2.4 million in c
Cyanotech Corporation (OTCQB:CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2025, ended June 30, 2024. Commenting on the first quarter fiscal year 2025 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "This quarter's net sales increased 15% as compared to prior year primarily due to increased sales of Astaxanthin in both our bulk and packaged markets. As we continue to expand our product offerings, we were excited to launch our Hawaiian Spirulina® gummies in May to complement the Astaxanthin gummy product." "Our growth in sales f
Cyanotech Corporation (OTCQB Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2024, ended March 31, 2024. Commenting on the fiscal year results (changes shown vs. fiscal 2023), Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Although the year was filled with challenges, our team effectively managed spending, production and inventory to conclude the year with only slightly increased debt of $209,000. As we look forward to this next year, and the increasing interest we are currently seeing in our products along with new product offe
The new gummy offers an industry-leading 12mg of Hawaiian Astaxanthin® per serving – 6000 times the antioxidant power of Vitamin C – with science-backed, multifunctional benefits and a 40-year legacy of farm-direct transparency and traceability. Nutrex-Hawaii, Inc., a wholly owned subsidiary of Cyanotech Corporation, unveils its #1 selling BioAstin® Hawaiian Astaxanthin® dietary supplement in a groundbreaking sugar free gummy format, enriched with an industry-leading 12mg of natural Hawaiian Astaxanthin per daily serving. At the forefront of natural microalgae innovation, Nutrex-Hawaii addresses the evolving preferences of today's discerning consumers with its new gummies, offering a ho
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the third quarter and first nine months of fiscal year 2024, ended December 31, 2023. Commenting on the third quarter fiscal year 2024 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "The macroeconomic environment led to lower sales across the portfolio on a year-to-date basis, being driven particularly by Spirulina bulk sales. Industry data shows consumers are not pulling back from dietary supplements, but they have begun trading down to private label brands to save on c
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter and first six months of fiscal year 2024, ended September 30, 2023. Commenting on the second quarter fiscal year 2024 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "The sales in the quarter are trending in the right direction with a 23.1% increase versus prior year. We generated cash flow from operations in the quarter of $0.8 million as we manage our spend in line with customer demand." "We continue to focus on driving demand in the naturally deriv
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2024, ended June 30, 2023. Commenting on the first quarter fiscal year 2024 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "This quarter we continue to see the impact of consumers shifting their spend from goods to experiences and services and reallocation of spending related to the high cost of living. Due to these shifting consumer trends, we have added a new position to the Company, Chief Strategic and Commercial Officer, to oversee an
Cyanotech Corporation (Nasdaq Capital Market: CYAN), the world innovation leader in the cultivation and manufacture of microalgae for health and nutrition, including BioAstin® Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica®, today announces the appointment of Collette Kakuk as Chief Strategic and Commercial Officer. Ms. Kakuk brings an impressive background in business development, strategy, and marketing to add significant value to Cyanotech's growing stable of products. Her industry experience, combined with a passionate drive for sustainable and authentic product sourcing, makes her an ideal addition to Cyanotech's executive team. Recognizing growing global interest in microalgae
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2023, ended March 31, 2023. Commenting on the fiscal year results (changes shown vs. fiscal 2022), Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Fiscal year 2023 was a challenging year as a result of a number of macroeconomic events and timing of sales. Consumers shifted their spend from goods to experiences and services. Lower sales in the bulk business were due in part to inventory adjustments after the global supply chain issues eased and l
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the third quarter and first nine months of fiscal year 2023, ended December 31, 2022. Commenting on the third quarter fiscal year 2023 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "Sales in the third quarter improved by $712,000, or 14%, compared to the second quarter, as we saw modest improvement in consumer movement on both finished goods and bulk sales. However, both of our online finished good sales and our international bulk sales are still not performing to histori
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the second quarter and first six months of fiscal year 2023, ended September 30, 2022. Commenting on the second quarter fiscal 2023 results, Cyanotech's President and Chief Executive Officer, Matthew K. Custer, said: "The financial results for the quarter, compared to the same period last year, had net sales decrease driven by a confluence of events, including the increased U.S. dollar exchange rate affecting international sales, lower sales in the bulk business, primarily in Asia, due in part to inventory adj
8-K - CYANOTECH CORP (0000768408) (Filer)
8-K - CYANOTECH CORP (0000768408) (Filer)
10-Q - CYANOTECH CORP (0000768408) (Filer)
DEF 14A - CYANOTECH CORP (0000768408) (Filer)
ARS - CYANOTECH CORP (0000768408) (Filer)
PRE 14A - CYANOTECH CORP (0000768408) (Filer)
10-K - CYANOTECH CORP (0000768408) (Filer)
8-K - CYANOTECH CORP (0000768408) (Filer)
10-Q - CYANOTECH CORP (0000768408) (Filer)
8-K - CYANOTECH CORP (0000768408) (Filer)
The Dow Jones index closed lower by more than 500 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Retractable Technologies The Trade: Retractable Technologies, Inc. (NYSE:RVP) President and CEO Thomas J Shaw bought a total of 12,710 shares at an average price of $1.13. To acquire these shares, it cost around $14,352. What's Happening:
The Dow Jones index closed higher by more than 700 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Alpha Teknova The Trade: Alpha Teknova, Inc. (NASDAQ:TKNO) 10% owner Telegraph Hill Partners Management Company, LLC bought a total of 12,096,773 shares at an average price of $1.24. To acquire these shares, it cost around $15 million. The co
The Dow Jones index closed higher by more than 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. ARCA biopharma The Trade: ARCA biopharma, Inc. (NASDAQ:ABIO) 10% owner Janus Henderson Biotech Innovation Master Fund Ltd bought a total of 408,777 shares at an average price of $3.49. To acquire these shares, it cost around $1.4 million. W
The Dow Jones index closed higher by over 400 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Expensify The Trade: Expensify, Inc. (NASDAQ:EXFY) 10% owner SF Roofdeck GP LLC bought a total of 123,217 shares at an average price of $1.45. To acquire these shares, it cost around $178,665. What's Happening: On June 14, JMP Securities anal
The Dow Jones index closed lower by around 100 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Brightcove The Trade: Brightcove Inc. (NASDAQ:BCOV) 10% owner Jonathan Brolin acquired a total of 41,747 shares an average price of $1.86. To acquire these shares, it cost around $77,667. The company’s CEO also bought 25,000 shares of the compa
Gainers Bit Brother (NASDAQ:BETS) shares rose 55.4% to $2.77 during Thursday's regular session. The market value of their outstanding shares is at $1.7 million. Guardion Health Sciences (NASDAQ:GHSI) shares increased by 13.94% to $8.5. The market value of their outstanding shares is at $10.8 million. China Jo-Jo Drugstores (NASDAQ:CJJD) shares moved upwards by 12.66% to $0.2. The market value of their outstanding shares is at $6.7 million. Maison Solutions (NASDAQ:MSS) stock rose 12.26% to $1.1. The company's market cap stands at $21.6 million. Webuy Global (NASDAQ:WBUY) shares rose 12.2% to $0.5. The company's market cap stands at $26.2 million. Chanson International (NASDAQ:CHSN) sha
Cyanotech (NASDAQ:CYAN) reported quarterly losses of $(0.16) per share. This is a 60 percent decrease over losses of $(0.10) per share from the same period last year. The company reported $5.58 million in sales this quarter. This is a 5.25 percent decrease over sales of $5.89 million the same period last year.
The Dow Jones index closed higher by around 250 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Cyanotech The Trade: Cyanotech Corporation (NASDAQ:CYAN) Director Michael Davis acquired a total of 400,000 shares an average price of $1.00. To acquire these shares, it cost around $400,000. What’s Happening: On Nov. 8, Cyanotech posted a na
The Dow Jones closed lower by around 40 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. FTC Solar The Trade: FTC Solar, Inc. (NASDAQ:FTCI) Director Ahmad Chatila acquired a total of 14,550 shares an average price of $0.68. To acquire these shares, it cost around $9,894. What’s Happening: On Nov. 8, FTC Solar reported mixed third-quarter f
Cyanotech (NASDAQ:CYAN) reported quarterly losses of $(0.13) per share. This is a 13.33 percent increase over losses of $(0.15) per share from the same period last year. The company reported $6.37 million in sales this quarter. This is a 23.05 percent increase over sales of $5.18 million the same period last year.
SC 13D/A - CYANOTECH CORP (0000768408) (Subject)
SC 13D/A - CYANOTECH CORP (0000768408) (Subject)
SC 13D/A - CYANOTECH CORP (0000768408) (Subject)
SC 13D/A - CYANOTECH CORP (0000768408) (Subject)
SC 13D/A - CYANOTECH CORP (0000768408) (Subject)
SC 13D/A - CYANOTECH CORP (0000768408) (Subject)
SC 13D/A - CYANOTECH CORP (0000768408) (Subject)
SC 13D/A - CYANOTECH CORP (0000768408) (Subject)
SC 13D - CYANOTECH CORP (0000768408) (Subject)
SC 13G/A - CYANOTECH CORP (0000768408) (Subject)